With Phase II pediatric data now reported and Phase III underway, LEO Pharma is continuing to build the clinical evidence base for expanding tralokinumab's use in younger patients with atopic dermatitis.
With Phase II pediatric data now reported and Phase III underway, LEO Pharma is continuing to build the clinical evidence base for expanding tralokinumab's use in younger patients with atopic dermatitis.